Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
Authors:
- Akihiko GemmaAGAkihiko Gemma
- Cai LiCLCai Li
- Yuka SugiyamaYSYuka Sugiyama
- Kuniko MatsudaKMKuniko Matsuda
- Seiji KosaihiraSKSeiji Kosaihira
- Yuji MinegishiYMYuji Minegishi
- Rintaro NoroRNRintaro Noro
- Michiya NaraMNMichiya Nara
- Masahiro SeikeMSMasahiro Seike
- Akinobu YoshimuraAYAkinobu Yoshimura
- Aki ShionoyaASAki Shionoya
Open Access
- 30 June 2006
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 174
Abstract
Background: The effect of current therapies in improving the survival of lung cancer patients remains far from satisfactory. It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an improved chemotherapeutic strategy for advanced lung cancer. Methods: We related the cytotoxic activity of each of commonly used anti-cancer agents (docetaxel, paclitaxel, gemcitabine, vinorelbine, 5-FU, SN38, cisplatin (CDDP), and carboplatin (CBDCA)) to corresponding expression pattern in each of the cell lines using a modified NCI program. Results: We performed gene expression analysis in lung cancer cell lines using cDNA filter and high-density oligonucleotide arrays. We also examined the sensitivity of these cell lines to these drugs via MTT assay. To obtain our reproducible gene-drug sensitivity correlation data, we separately analyzed two sets of lung cancer cell lines, namely 10 and 19. In our gene-drug correlation analyses, gemcitabine consistently belonged to an isolated cluster in a reproducible fashion. On the other hand, docetaxel, paclitaxel, 5-FU, SN-38, CBDCA and CDDP were gathered together into one large cluster. Conclusion: These results suggest that chemotherapy regimens including gemcitabine should be evaluated in second-line chemotherapy in cases where the first-line chemotherapy did not include this drug. Gene expression-drug sensitivity correlations, as provided by the NCI program, may yield improved therapeutic options for treatment of specific tumor types.Keywords
This publication has 21 references indexed in Scilit:
- Heat Shock 70‐kDa Protein 8 Isoform 1 Is Expressed on the Surface of Human Embryonic Stem Cells and Downregulated upon DifferentiationStem Cells, 2005
- ALIMTA® (pemetrexed disodium) as second-line treatment ofnon-small-cell lung cancer: a phase II studyAnnals of Oncology, 2003
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Molecular cloning and characterization of a novel Dehydrogenase/reductase (SDR family) member 1 genea from human fetal brainMolecular Biology Reports, 2001
- Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles.2001
- Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell lineEuropean Journal of Cancer, 2001
- Somatic mutation of thehBUB1 mitotic checkpoint gene in primary lung cancerGenes, Chromosomes and Cancer, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2000